A retrospective chart review was performed on seven patients treated with topical ocular corticosteroid therapy for progressive cicatricial conjunctivitis associated with chronic graft-versus-host disease (GVHD) following hematopoietic stem cell transplantation. A clinical grading criteria for conjunctival GVHD based on the degree of cicatrization was developed and patients graded prior to therapy. During the treatment course, the dose and frequency of topical corticosteroids and clinical outcomes were recorded. A complete response was defined as a complete resolution of the conjunctival hyperemia with either total resolution of the conjunctival fibrovascularization or presence of inactive conjunctival scarring. Prednisolone acetate 1% eye drops were used in a total of eight courses of therapy in seven patients. A complete response was documented in all seven patients with a total treatment duration of 7 weeks (median, range: 3-16 weeks). Additional studies are required to determine the long-term safety and efficacy of topical corticosteroids for cicatricial conjunctivitis associated with ocular GVHD in the context of a randomized, prospective clinical trial.
Summary:
A retrospective chart review was performed on seven patients treated with topical ocular corticosteroid therapy for progressive cicatricial conjunctivitis associated with chronic graft-versus-host disease (GVHD) following hematopoietic stem cell transplantation. A clinical grading criteria for conjunctival GVHD based on the degree of cicatrization was developed and patients graded prior to therapy. During the treatment course, the dose and frequency of topical corticosteroids and clinical outcomes were recorded. A complete response was defined as a complete resolution of the conjunctival hyperemia with either total resolution of the conjunctival fibrovascularization or presence of inactive conjunctival scarring. Prednisolone acetate 1% eye drops were used in a total of eight courses of therapy in seven patients. A complete response was documented in all seven patients with a total treatment duration of 7 weeks (median, range: 3-16 weeks). Additional studies are required to determine the long-term safety and efficacy of topical corticosteroids for cicatricial conjunctivitis associated with ocular GVHD in the context of a randomized, prospective clinical trial. Hematopoietic stem cell transplantation (SCT) is commonly used to treat a number of nonmalignant and malignant diseases. [1] [2] [3] [4] A major complication of allogeneic SCT is chronic graft-versus-host disease (GVHD) which most commonly affects the skin, mouth, liver, and the eye. 5 Ocular complications of GVHD include conjunctival hyperemia, aqueous tear deficiency with keratoconjunctivitis sicca (KCS), pseudomembranous conjunctivitis, cicatricial conjunctivitis, corneal epithelial sloughing, and corneal ulceration. [6] [7] [8] [9] [10] [11] [12] Cicatricial conjunctivitis can lead to entropion, trichiasis, corneal ulceration, and vision loss. 7, 8, 13, 14 Systemic immunosuppressive therapy can be used to treat ocular GVHD; 5, [15] [16] [17] however, some patients with cicatricial conjunctivitis progress despite systemic treatment. 18 Herein, we reviewed our results using topical ocular corticosteroids for progressive cicatricial conjunctivitis from GVHD.
Materials and methods
This was a retrospective chart review of patients with cicatricial conjunctivitis from GVHD treated with topical corticosteroids at National Eye Institute from September 2002 to May 2003. Patients were enrolled in protocols using allogeneic stem cells from the peripheral blood of HLAidentical sibling donors for the treatment of malignant diseases. Topical corticosteroids were used to treat progressive cicatricial conjunctivitis in patients not responding to systemic immunosuppression or in patients where initiating or increasing the dosing of the immunosuppressant medications was not recommended by the oncologist. Recorded data from eye examinations included ocular symptoms, visual acuity, and pathology documented from slit-lamp biomicroscopy. Schirmer's scoring was performed using proparacaine 0.5% eye drops (measured in millimeters at 5 min) and were recorded only in patients that did not have punctal occlusion. The only grading criteria in the literature for conjunctival GVHD was principally for patients with acute GVHD and included the presence of pseudomembranous conjunctivitis, 9 a sign rarely observed in patients with chronic GVHD. 19, 20 We developed a clinically relevant grading criteria for conjunctival GVHD based on the conjunctival pathology observed in our patients with chronic GVHD (Figure 1 ). Grade 1 is defined as conjuctival hyperemia occurring on the bulbar or palpebral conjunctiva in at least one eyelid. Grade 2 has palpebral conjunctival fibrovascular changes occurring along the superior border of the upper eyelid, or the lower border of the tarsal plate of the lower eyelid, with or without conjunctival epithelial sloughing, involving o25% of the total surface area in at least one eyelid. Grade 3 is defined as palpebral conjunctival fibrovascular changes occurring along the superior border of the upper eyelid, or the lower border of the tarsal plate of the lower eyelid, involving 25-75% of the total surface area in at least one eyelid. Grade 4 involves 475% of the total surface area with or without a cicatricial entropion in at least one eyelid. During the treatment course with ocular topical corticosteroids, conjunctival GVHD grading scores, dose and frequency of topical ocular corticosteroids, and clinical outcomes were recorded. A complete response was defined as complete resolution of the conjunctival hyperemia with either total resolution of the conjunctival fibrovascularization or presence of inactive, nonvascular, conjunctival scarring. A partial response was a 50% reduction in conjunctival hyperemia with no progression of the conjunctival fibrovascularization.
Results
A chart review identified seven patients treated with topical corticosteroids for progressive cicatricial conjunctivitis. All the patients had pre-existing active chronic GVHD with oral involvement and five patients had X2 active organ systems in addition to the conjunctival involvement (Table  1a and b). All patients were symptomatic complaining of eye irritation and redness. All patients had active conjunctival disease despite the use of oral immunosuppressive agents in five patients. The conjunctival GVHD disease grading at presentation in all patients were either Grade 2 or Grade 3. Prednisolone acetate 1% eye drops were used in a total of eight courses of therapy in seven patients. A complete response was documented in all seven patients with a total treatment duration of 7 weeks (median, range: 3-16 weeks) ( Figure 2 ). All patients reported a resolution of their symptoms of ocular redness and a reduction in ocular irritation. Six patients still complained of dry eyes and required frequent topical lubrication. The total length of follow-up for all patients after initiating the topical ocular corticosteroid therapy was 6 months (median, range: 2-10 months). Only one patient (case 2) had a flare of the conjunctival GVHD occurring 6 months after finishing the first course of topical ocular corticosteroid therapy. This flare was treated again with prednisolone acetate 1% eye drops and a complete response was documented after 3 weeks of therapy. Five patients had Schirmer's scores that could be evaluated and of the four patients with scores o5 mm at the initiation of the treatment, one patient had an improvement in Schirmer's scores (X5 mm) with therapy. Corticosteroid-induced ocular hypertension occurred in both eyes of three patients with a median increase of 14 mm Hg (range: 6-19 mmHg) from baseline. Two patients required a topical ocular antihypertensive agent to control the eye pressure and this was discontinued following the topical ocular corticosteroid treatment course. No secondary infections, such as bacterial or viral conjunctivitis, occurred with the use of the topical corticosteroids.
The concomitant use of systemic immunosuppressive medications during the topical ocular corticosteroid treatment course was reviewed for each patient (Table 1a and b) . Although five patients were on systemic immunosuppression at the start of topical ocular corticosteroid therapy, only two patients had an additional immunosuppressive medication started during the topical ocular corticosteroid treatment course for reasons unrelated to ocular GVHD. However, both of the patients had already been started on a tapering schedule of topical ocular corticosteroids because of a positive response, and it is unlikely that the additional systemic immunosuppressant had a significant impact on the outcome of the conjunctival disease. During the topical corticosteroid ocular treatment course, none of the patients had resolution of GVHD activity in other involved organ sites.
Discussion
The treatment of patients with cicatricial conjunctivitis associated with ocular GVHD using topical ocular Topical therapy for cicatricial conjunctivitis MR Robinson et al corticosteroids appeared to be effective in this small case series. In the literature, topical ocular corticosteroids were not effective in the treatment of pseudomembranous conjunctivitis occurring in the setting of advanced acute GVHD. 6, 9 All our patients with cicatricial conjunctivitis had active chronic GVHD, a group of patients that can also respond to topical corticosteroids for oral mucosal, 16 vaginal mucosal, 21 skin, 16 and gastrointestinal GVHD. 22 Topical corticosteroid therapy for organ-specific GVHD can reduce the need for systemic immunosuppression, which may benefit patients requiring an enhanced graftversus-tumor effect. It was interesting that topical ocular corticosteroid therapy followed by a gradual taper appeared effective in our series since treatment of mucosal manifestations of chronic GVHD often requires the prolonged use of systemic immunosuppressive agents. 21 This philosophy of higher initial doses of corticosteroids followed by a taper was used by Akpek et al 23 for treating refractory systemic chronic GVHD and they achieved a high response rate with Footnotes: see Table 1a .
Topical therapy for cicatricial conjunctivitis MR Robinson et al a quarter of the patients able to discontinue all systemic immunosuppressive medications. The high ocular drug concentrations that can be achieved with topical corticosteroids compared with systemic administration 24 can promote lymphocyte apoptosis and suppress cell-mediated inflammation. 25, 26 This is of special relevance in patients with ocular GVHD where the primary inflammatory cell present histologically is the T lymphocyte. 9, 27, 28 However, treating patients with topical ocular corticosteroids must be managed by an ophthalmologist to monitor for sightthreatening conditions such as corticosteroid-induced glaucoma, cataracts, infectious keratitis, and corneal thinning. 29, 30 The pathogenesis of cicatricial conjunctivitis associated with GVHD is not clear but may represent a response to tissue injury associated with conjunctival sloughing and ulceration. Patients with skin and oral mucosal GVHD develop a similar pattern of tissue injury that may result in tissue ulceration and fibrovascularization in the chronic stages. 21 The location of the inflammatory and cicatricial changes, starting most commonly along the superior border of the tarsus in the upper eyelids, may be important in the pathogenesis of the aqueous tear deficiency seen with KCS in GVHD patients. The assessory lacrimal glands located in this area contribute significantly to basal tear production 31 and become involved early in the inflammatory process. 8 In case 1, the patient had aqueous tear deficiency that was reversed with the use of topical ocular corticosteroids. However, the other cases had either long-standing aqueous tear dysfunction or extensive inflammatory changes likely resulting in assessory lacrimal gland injury not recoverable with topical corticosteroid therapy. There are a number of limitations in the interpretation of the data in this retrospective study. The management of cicatricial conjunctivitis, especially in patients that may develop frequent flares, would require longer follow-up to fully evaluate the safety and efficacy of topical corticosteroids. Other limitations include no standardization in the topical ocular corticosteroid treatment regimen and no formal assessment of visual function and ocular symptoms were performed during the treatment course. In addition, the apparent clinical improvement of cicatricial conjunctivitis with topical corticosteroids might also be related to other factors such as the concomitant use of systemic immunosuppression in some of the patients. Lastly, there were no patients with Grade 4 conjunctival GVHD and the effects of topical ocular corticosteroid therapy in this more advanced disease group are not known.
The prevalence of chronic GVHD continues to increase in tandem with improved survival rates after allogeneic SCT. To reduce the morbidity associated with chronic GVHD, new therapeutic approaches to reverse and prevent progression of ocular manifestations are critically needed. This retrospective analysis suggests a positive effect using topical ocular corticosteroids for treating cicatricial conjunctivitis associated with GVHD. Further investigation in the context of a randomized, prospective clinical trial is recommended using a composite GVHD staging system incorporating standardized assessments of patient symptoms and relevant grading scales for quantifying tear function and measuring the severity of corneal and conjunctival disease.
